Financials
- Market Capitalization 8.16 B
- Employee 691
- Founded 2014
- CEO Rich Adcock
- Website www.immunitybio.com
- Headquarter Delaware, United States
- FIGI BBG007T9DYW9
- Industry Biotechnology
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 1012 | APGE Apogee Therapeutics, Inc. - Common Stock | 133.82 USD | +0.13% | +0.25% | +49.25% | +149.71% | 8.28 B USD | ||
| 1016 | PCVX Vaxcyte, Inc. - Common Stock | 57.03 USD | -2.03% | -1.30% | +19.53% | +34.82% | 8.23 B USD | ||
| 1026 | SYRE Spyre Therapeutics, Inc. - Common Stock | 93.73 USD | -4.10% | +5.46% | +14.91% | +292.01% | 8.14 B USD | ||
| 1041 | IMVT Immunovant, Inc. - Common Stock | 38.70 USD | -2.54% | -0.77% | +14.50% | +101.46% | 7.95 B USD |
Frequently asked questions about ImmunityBio, Inc. - Common Stock
What is the ImmunityBio, Inc. - Common Stock stock price today?
The current price of ImmunityBio, Inc. - Common Stock (IBRX) is 7.79. Over the past 24 hours, the stock has changed by -5.23%. Follow the IBRX chart for real-time price dynamics.
What is the stock ticker of ImmunityBio, Inc. - Common Stock?
ImmunityBio, Inc. - Common Stock trades under the ticker IBRX. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is ImmunityBio, Inc. - Common Stock stock going up?
IBRX has changed by -13.06% over the last week, +7.45% over the last month, and +166.78% over the last year. Review the chart to see whether the current move is part of a broader trend.
What was ImmunityBio, Inc. - Common Stock net income for the last quarter?
ImmunityBio, Inc. - Common Stock reported net income of -632.78 M for the last quarter. The previous quarter showed -61.94 M, which means net income changed by -921.54%.
How many employees does ImmunityBio, Inc. - Common Stock have?
As of the latest available data, ImmunityBio, Inc. - Common Stock has 691 employees. Workforce size can provide additional context about the company's scale and operations.
What is ImmunityBio, Inc. - Common Stock EBITDA?
ImmunityBio, Inc. - Common Stock EBITDA is -65.41 M, and its EBITDA margin is -147.97%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy ImmunityBio, Inc. - Common Stock stock?
You can buy ImmunityBio, Inc. - Common Stock (IBRX) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in ImmunityBio, Inc. - Common Stock stock?
Investing in ImmunityBio, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the IBRX chart and related analysis on metatrader.com as part of your research.